-
Loading metrics
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors
- Yasuki Hijikata,
- Toshihiko Okazaki,
- Yoshihiro Tanaka,
- Mutsunori Murahashi,
- Yuichi Yamada,
- Kazunari Yamada,
- Atsushi Takahashi,
- Hiroyuki Inoue,
- Junji Kishimoto,
- Yoichi Nakanishi
x
- Published: January 2, 2018
- https://doi.org/10.1371/journal.pone.0187878